Much of the discussion focused on the likely impact of the ongoing global economic downturn, the threat of biosimilars and US healthcare on biotechnology sector.
On a more positive note, Ernst & Young predicted that while the economic climate is difficult for biotechnology firms at the moment those that do survive are likely to do so due to effective business models, making for a stronger sector in years to come.
Another theme of the event was the importance of collaboration, both between biotech firms themselves and with players in the wider global pharmaceutical industry.